


Multinational Pharmaceutical Companies Shortchange Canada in Research and Development Investments: Is It Time to Pursue Other Options?

Les sociétés pharmaceutiques multinationales bernent le Canada en matière d'investissements en recherche et développement : est-il temps de rechercher de nouvelles façons de faire?

SHOO K. LEE, SUKHY K. MAHL, JESSICA J. GREEN AND JOEL LEXCHIN


Appendix 1: Figures A1 and A2

FIGURE A1: Pharmaceutical company spending on R&D vs. pharmaceutical expenditures per capita, in USD, in several OECD countries in 1987



PPP = purchasing power parity; R&D = research and development.

FIGURE A2: Pharmaceutical company spending on R&D vs. pharmaceutical expenditures per capita, in USD, in several OECD countries in 2017



PPP = purchasing power parity; R&D = research and development.